| Deanna Willis, MS CF SLP | |
|
6855 W Fairview Ave, Ster 120, Boise, ID 83704-8046 | |
| (208) 323-8888 | |
| Not Available |
| Full Name | Deanna Willis |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 6855 W Fairview Ave, Boise, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275806572 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Deanna Willis, MS CF SLP 3925 Normandie Dr, Boise, ID 83705-4732 Ph: (208) 323-8888 | Deanna Willis, MS CF SLP 6855 W Fairview Ave, Ster 120, Boise, ID 83704-8046 Ph: (208) 323-8888 |
News Archive
"They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals (cats)," writes the team. "The work here lays the framework for their use in human trials for the treatment of COVID-19."
Northwestern Medicine received a $10 million gift to fund the creation of a new multidisciplinary institute dedicated to urologic cancers.
The artificial intelligence that can blow human pilots out of the sky in air-to-air combat accurately predicted treatment outcomes for bipolar disorder, according to a new medical study by the University of Cincinnati.
Babies born early run a greater risk of serious complications. The researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have now developed a method to predict if pregnant women with preterm contractions will give birth within seven days. The method offers new possibilities to delay delivery and prepare care for the premature baby.
AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.
› Verified 8 days ago
Jennifer Dahms, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2995 N Cole Rd, Suite 130, Boise, ID 83704 Phone: 208-559-2348 Fax: 888-559-4660 | |
Lauren Rose Addison, M.S. SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 8620 W Emerald St Ste 100, Boise, ID 83704 Phone: 208-898-1368 | |
Kelli Shaw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3115 N Sycamore Dr, Boise, ID 83703 Phone: 208-401-6401 | |
Christy Baltazor, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Megan Patrick, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Emily Chapman, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8860 W Evening Star Ln, Boise, ID 83709 Phone: 814-873-9144 | |
Kimberly Degraw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 901 N Curtis Rd Ste 204, Boise, ID 83706 Phone: 208-367-8282 |